Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Harter P, Mouret-Reynier MA, Pignata S, Cropet C, González-Martín A, Bogner G, Fujiwara K, Vergote I, Colombo N, Nøttrup TJ, Floquet A, El-Balat A, Scambia G, Guerra Alia EM, Fabbro M, Schmalfeldt B, Hardy-Bessard AC, Runnebaum I, Pujade-Lauraine E, Ray-Coquard I. Harter P, et al. Among authors: el balat a. Gynecol Oncol. 2022 Feb;164(2):254-264. doi: 10.1016/j.ygyno.2021.12.016. Epub 2021 Dec 22. Gynecol Oncol. 2022. PMID: 34952708 Free article. Clinical Trial.
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators. Coleman RL, et al. Lancet. 2017 Oct 28;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12. Lancet. 2017. PMID: 28916367 Free PMC article. Clinical Trial.
Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marmé F, Heimbach A, Prieske K, Richters L, Burges A, Neidhardt G, de Gregorio N, El-Balat A, Hilpert F, Meier W, Kimmig R, Kast K, Sehouli J, Baumann K, Jackisch C, Park-Simon TW, Hanker L, Kröber S, Pfisterer J, Gevensleben H, Schnelzer A, Dietrich D, Neunhöffer T, Krockenberger M, Brucker SY, Nürnberg P, Thiele H, Altmüller J, Lamla J, Elser G, du Bois A, Hahnen E, Schmutzler R. Harter P, et al. PLoS One. 2017 Oct 20;12(10):e0186043. doi: 10.1371/journal.pone.0186043. eCollection 2017. PLoS One. 2017. PMID: 29053726 Free PMC article.
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Chekerov R, Hilpert F, Mahner S, El-Balat A, Harter P, De Gregorio N, Fridrich C, Markmann S, Potenberg J, Lorenz R, Oskay-Oezcelik G, Schmidt M, Krabisch P, Lueck HJ, Richter R, Braicu EI, du Bois A, Sehouli J; NOGGO; AGO TRIAS Investigators. Chekerov R, et al. Lancet Oncol. 2018 Sep;19(9):1247-1258. doi: 10.1016/S1470-2045(18)30372-3. Epub 2018 Aug 9. Lancet Oncol. 2018. PMID: 30100379 Clinical Trial.
What is the evidence for lymphadenectomy in presumed early ovarian cancer?
Schmalfeldt B, Brambs C, Burges A, El-Balat A, Emons G, Fink D, Fotopoulou C, Gropp-Meier M, Hanker LC, Harter P, Hasenburg A, Hauptmann S, Hilpert F, Kimmig R, Kommoss S, Kurzeder C, Mahner S, Marmé F, Mayr D, Meier W, Meinhold-Heerlein I, Mustea A, Ortmann O, Oskay-Özcelik G, Pfisterer J, Pölcher M, Runnebaum IB, Schröder W, Tanner B, Wagner U, Wimberger P, Sehouli J. Schmalfeldt B, et al. Arch Gynecol Obstet. 2019 Jan;299(1):1-5. doi: 10.1007/s00404-018-4945-8. Arch Gynecol Obstet. 2019. PMID: 30374648 No abstract available.
Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group.
Canzler U, Lück HJ, Neuser P, Sehouli J, Burges A, Harter P, Schmalfeldt B, Aminossadati B, Mahner S, Kommoss S, Wimberger P, Pfisterer J, de Gregorio N, Hasenburg A, Gropp-Meier M, El-Balat A, Jackisch C, du Bois A, Meier W, Wagner U. Canzler U, et al. Arch Gynecol Obstet. 2020 May;301(5):1267-1274. doi: 10.1007/s00404-020-05529-y. Epub 2020 Apr 10. Arch Gynecol Obstet. 2020. PMID: 32277253
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Pfisterer J, et al. Lancet Oncol. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16. Lancet Oncol. 2020. PMID: 32305099 Free article. Clinical Trial.
Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in BRCA1/2: results of the observational AGO-TR1 study (NCT02222883).
Hauke J, Harter P, Ernst C, Burges A, Schmidt S, Reuss A, Borde J, De Gregorio N, Dietrich D, El-Balat A, Kayali M, Gevensleben H, Hilpert F, Altmüller J, Heimbach A, Meier W, Schoemig-Markiefka B, Thiele H, Kimmig R, Nürnberg P, Kast K, Richters L, Sehouli J, Schmutzler RK, Hahnen E. Hauke J, et al. J Med Genet. 2022 Mar;59(3):248-252. doi: 10.1136/jmedgenet-2020-107353. Epub 2020 Dec 3. J Med Genet. 2022. PMID: 33273034 Free PMC article.
Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study.
Cibula D, Dostalek L, Hillemanns P, Scambia G, Jarkovsky J, Persson J, Raspagliesi F, Novak Z, Jaeger A, Capilna ME, Weinberger V, Klat J, Schmidt RL, Lopez A, Scibilia G, Pareja R, Kucukmetin A, Kreitner L, El-Balat A, Pereira GJR, Laufhütte S, Isla-Ortiz D, Toptas T, Gil-Ibanez B, Vergote I, Runnenbaum I. Cibula D, et al. Eur J Cancer. 2021 Jan;143:88-100. doi: 10.1016/j.ejca.2020.10.037. Epub 2020 Dec 5. Eur J Cancer. 2021. PMID: 33290995
38 results